Given that the United States proceeds with historic changes to its immunization schedules, a particular individual has surfaced somewhat surprisingly: Høeg, a US-based sports physician and public health researcher who first made her name by casting doubt on Covid vaccinations in the global health crisis and has focused upon potential fatalities after COVID-19 immunization in her brief tenure at the FDA.
Proposed Changes to Childhood Immunization Program
Public health authorities were set to announce radical changes to the childhood immunization program earlier this month, synchronizing the US with the Danish immunization schedule, according to reports – a major change that would place the US out of alignment with a large portion of the world with insufficient data for improved outcomes. This reveal has been delayed until the coming year.
Rather than the director of the vaccine center, Høeg is listed to present at the meeting. She was recently named interim head of the FDA’s drug evaluation center, the fifth individual to lead the division this calendar year.
A New Direction at the FDA
The acting appointment may indicate a tighter collaboration between the drug and biologics centers as Dr. Høeg and Prasad solidify control at the FDA – and it suggests a increased emphasis upon dismantling previously authorized immunizations at the FDA.
The new acting director has frequently advocated for discontinuing certain pediatric shot schedules in the US so as to align more similar to the Danish model, a country with universal health coverage and a population approximately the population of Wisconsin’s.
In her initial comments, she has continued to focus on vaccination policy – typically the domain of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.
Questions Over Background
Høeg has no apparent experience in pharmaceutical research, oversight or management, which has been customary for former directors of the CBER. She has served at the FDA as a senior adviser to the commissioner and CBER since March.
“She appears not to have the requisite experience” for leading the pharmaceutical oversight division, stated a neurologist and psychiatrist. “She has not conducted a clinical trial. She is not versed in running a major agency. She lacks background in pharmaceutical oversight.”
Previous commissioners of CBER would “be deeply familiar with regulatory frameworks and the science of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Frankly, she doesn’t have the sort of resume that former directors who ran CBER have had.”
This division has an enormous range of responsibilities at the FDA, she pointed out.
“The public just focuses on the new drug program, but the off-patent medication office clears numerous generic medications. There’s a biosimilars program, OTC medication office and more, and every single one have to be managed,” Dr. Woodcock said. “The responsibility you overlook, that is precisely what that I always told people is going to cause problems.”
Additionally, a major management element to the role, which supervises more than 5,000 employees. “It’s a huge administrative position, if you do it right,” she added.
Response and Disputed Initiatives
When asked about inquiries about Høeg’s credentials and whether this assignment represents greater collaboration among agency officials on vaccines, a representative responded that the “concerns rely on incorrect presumptions”.
“This background matches the functions of her position,” the representative explained, pointing to the time Høeg spent advising the FDA commissioner on “drug safety and regulatory science, including computational safety modeling and shot safety tracking”.
In her interim role, Høeg assumes responsibility for the agency head's new fast-track approval initiative, a controversial one-day drug-approval program that reportedly troubled her preceding directors. “By what process are these drugs being selected for this fast-track system? Who takes the choices?” Howard questioned. “There’s a lot of confidentiality going on at the regulatory body right now.”
Overall, he stated, “the agency looks to be trending towards less stringent oversight of most medications, aside from immunizations.”
Established Past Work on Immunizations
Regarding immunizations, Dr. Høeg has a more established, if concerning, past, critics observe. She authored a study using non-validated crowd-sourced reports to estimate the frequency of myocarditis following Covid immunization. She consulted for the state of Florida surgeon general Dr. Joseph Ladapo, who allegedly have changed statistics to indicate COVID-19 vaccines are riskier than they are.
Among her “policy goals” for the incoming federal leadership included revising rules for recently developed shots and halting “unnecessary” immunizations, she stated post-election on a online show. At the agency, Høeg has according to sources proposed barring young men from getting Covid vaccines.
“She’s an thorough true believer who commences with her conclusions and reverse-engineers to fit the science in a extremely misleading, fraudulent manner,” Dr. Howard argued.
Gaining Influence and a “Push for Payback”
Høeg joined fellow contrarians, {like|